Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Generico de prolia?

See the DrugPatentWatch profile for prolia

What is Prolia and its Generic Equivalents?

Prolia, with the active ingredient denosumab, is a prescription medication used to treat osteoporosis in postmenopausal women at high risk for fracture, men at high risk for fracture, and adults with bone loss due to certain cancer treatments [1]. It is also used to treat giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [1]. Prolia works by inhibiting osteoclast activity, which reduces bone breakdown [2].

As of now, there are no approved generic versions of Prolia available in the United States [3]. The drug is manufactured by Amgen [1].

When Can Generic Versions of Prolia Be Expected?

The availability of generic drugs typically follows the expiration of patents and other market exclusivities held by the innovator company. Patent information for drugs can be complex, often involving multiple patents covering different aspects of the drug, such as its composition, method of use, and manufacturing process [4].

Companies that develop generic versions of a drug must navigate these patent landscapes. Often, generic manufacturers will challenge existing patents or wait for them to expire before launching their products [4]. Information regarding the patent status and potential for generic entry for specific drugs can be found on resources like DrugPatentWatch.com [5].

How Does Prolia Work?

Prolia is a human monoclonal antibody that targets RANK ligand (RANKL) [2]. RANKL is a protein that plays a critical role in the formation, function, and survival of osteoclasts, the cells responsible for bone resorption (breakdown) [2]. By binding to RANKL, denosumab prevents it from interacting with its receptor, RANK, on the surface of osteoclast precursors and mature osteoclasts [2]. This inhibition ultimately reduces osteoclast activity and bone resorption, leading to increased bone mineral density and a reduced risk of fractures [2].

What Are the Risks Associated with Prolia?

Like all medications, Prolia carries potential risks and side effects. Common side effects include pain in the extremities, muscle spasms, and urinary tract infections [1]. More serious but less common side effects can include hypocalcemia (low calcium levels), severe allergic reactions, osteonecrosis of the jaw, and atypical femur fractures [1]. Patients should discuss their medical history and any concerns with their healthcare provider before starting Prolia [1].

Sources

1. https://www.prolia.com/
2. https://www.drugbank.ca/drugs/DB01405
3. Food and Drug Administration (FDA) generic drug approval databases. (Information based on current availability as of [insert current date or state that information is based on available data]).
4. https://www.drugpatentwatch.com/
5. https://www.drugpatentwatch.com/



Other Questions About Prolia :

prolia patentablauf Price prolia in us? Prolia injection cost? Prolia subcutaneous injection? Prolia cost in usa? Side effects of prolia? What is the cost of a prolia injection?

AI-Drug Label Prescribing Information Alignment Report

86
86%
Grade B

Good

Partially Aligned

Patient Risk: Moderate

Summary

Most safety-related claims are consistent with the provided label excerpts (especially hypocalcemia risk in advanced CKD). However, the evaluation is limited because the provided label text only contains specific sections on hypocalcemia/mineral metabolism and does not substantiate many other claims (e.g., indications, mechanism details, specific adverse reactions).


Category Scores

Indication
35
Poor
Dosage
0
Poor
Warnings
90
Good
SpecificPopulations
95
Excellent
AdverseReactions
55
Partial

Accurate Statements

In patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m2), including dialysis-dependent patients, Prolia is associated with a greater risk of severe hypocalcemia, which can include hospitalization, life-threatening events, and fatal cases.
Supported by Warnings & Precautions (5.1 Patients with Advanced Chronic Kidney Disease), Use in Specific Populations (8.6 Renal Impairment), Adverse Reactions postmarketing (6.2), and Patient Counseling (17).

Unsupported Statements

Prolia contains the active ingredient denosumab.
Not supported by the provided label excerpts.
Prolia is a prescription medication used to treat osteoporosis in postmenopausal women at high risk for fracture.
Indication claims are not supported by the provided label excerpts.
Prolia is used to treat men at high risk for fracture.
Indication claims are not supported by the provided label excerpts.
Prolia is used to treat adults with bone loss due to certain cancer treatments.
Indication claims are not supported by the provided label excerpts.
Prolia is used to treat giant cell tumor of bone that is unresectable.
Indication claims are not supported by the provided label excerpts.
Prolia is used to treat giant cell tumor of bone when surgical resection is likely to result in severe morbidity.
Indication claims are not supported by the provided label excerpts.
Prolia works by inhibiting osteoclast activity, which reduces bone breakdown.
Mechanism description is not supported by the provided label excerpts.
There are no approved generic versions of Prolia available in the United States.
Not supported by the provided label excerpts.
Prolia is manufactured by Amgen.
Not supported by the provided label excerpts.
Prolia is a human monoclonal antibody.
Not supported by the provided label excerpts.
Prolia targets RANK ligand (RANKL).
Mechanism/target claims are not supported by the provided label excerpts.
RANKL plays a critical role in the formation, function, and survival of osteoclasts.
Mechanism biology statements are not supported by the provided label excerpts.
Osteoclasts are responsible for bone resorption (breakdown).
Mechanism biology statements are not supported by the provided label excerpts.
Denosumab binds to RANKL and prevents it from interacting with its receptor RANK on the surface of osteoclast precursors and mature osteoclasts.
Mechanism binding interaction details are not supported by the provided label excerpts.
By inhibiting osteoclast activity and bone resorption, Prolia increases bone mineral density.
Clinical pharmacology/efficacy claim is not supported by the provided label excerpts.
By reducing osteoclast activity and bone resorption, Prolia reduces the risk of fractures.
Clinical pharmacology/efficacy claim is not supported by the provided label excerpts.
Common side effects of Prolia include pain in the extremities.
No 'common side effects' list for this specific symptom is provided in the label excerpts.
Common side effects of Prolia include muscle spasms.
No 'common side effects' list for this specific symptom is provided in the label excerpts.
Common side effects of Prolia include urinary tract infections.
No 'common side effects' list for this specific symptom is provided in the label excerpts.
Prolia can cause hypocalcemia (low calcium levels).
Hypocalcemia risk is supported in provided sections, but this statement is overly general and does not specify 'severe' hypocalcemia; still, it is partially supported. If strictly judged to the excerpts only, severe hypocalcemia is explicitly supported, not generic 'hypocalcemia' phrasing as 'can cause' without severity context.
Prolia can cause severe allergic reactions.
Not supported by the provided label excerpts.
Prolia can cause osteonecrosis of the jaw.
Not supported by the provided label excerpts.
Prolia can cause atypical femur fractures.
Not supported by the provided label excerpts.

Contradictions


Important Omissions

Any administration/dosing instructions and lab monitoring details required for safe use (e.g., calcium/vitamin D supplementation requirements; timing of serum calcium and mineral checks) for the broader set of claims beyond advanced CKD.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Only one evaluated claim (advanced CKD hypocalcemia risk including hospitalization/life-threatening/fatal cases) is directly supported by the provided label excerpts. Many other claims (indications, mechanism, and multiple adverse reactions) are not supported by the supplied label text, creating a risk of misinformation if relied upon.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Partially Aligned

Primary Issue
Most claims are not supported by the provided label excerpts; only the advanced CKD hypocalcemia warning is substantiated.

Suggested Improvement
Restrict the response to label-supported information from the provided excerpts (primarily severe hypocalcemia risk in advanced CKD, supplementation, and recommended monitoring), or provide the relevant label sections for indications, mechanism, and specific adverse reactions.

Drug Brand Mention Assessment

Branding Score
44
Visibility
50
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

prescription medication used to treat osteoporosis


Core Claims
  • Prolia is a prescription medication used to treat osteoporosis and other conditions.
  • There are no approved generic versions of Prolia available in the United States.
  • Prolia works by inhibiting osteoclast activity to reduce bone breakdown.
  • Prolia is associated with risks and side effects.
Differentiators
  • It uses the active ingredient denosumab.
  • It is used for osteoporosis and giant cell tumor of bone in certain cases.
  • It targets RANK ligand (RANKL) to inhibit osteoclast activity.

Pricing Perception: Not Mentioned